Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Psych MEQs / SAQsOld age psychiatry — residential care and systems of care

Psych MEQs / SAQs · Old age psychiatry — residential care and systems of care

Residential aged care psychiatry — behavioural crisis and prescribing (MEQ)

FRANZCP-style MEQ on RAC psychiatry: multifactorial assessment, person-centred care, pain protocol, antipsychotic mortality evidence, deprescribing, chemical restraint, capacity.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
An 84-year-old woman with moderate Alzheimer disease lives in a residential aged care facility. Over two weeks she has become more restless at night, strikes out during personal care, and has been given PRN risperidone almost daily. Staff say 'we cannot manage without it.' Family worry she is over-sedated and falls more. She is on oxybutynin and temazepam. There is no clear documentation of target symptoms, consent, or review date. (i) Outline a structured assessment of behavioural change in RAC, including medical and unmet-need drivers. (ii) Discuss non-pharmacological and organisational interventions with named evidence (Fossey, CADRES/WHELD, Husebo). (iii) Discuss antipsychotic benefits, harms (Schneider/Gill/Huybrechts), dosing philosophy if continued briefly, and deprescribing (DART-AD). (iv) Address chemical restraint, capacity/proxy consent, and disposition/liaison. (20 marks)

Model answer

Reveal model answer

(i) Assessment. Behavioural change in RAC is multifactorial. Structure: safety (aggression, falls, absconding); collateral from staff and family for time course and baseline; medical screen for delirium, infection, pain, constipation, retention, dehydration, hypoxia; medication review (oxybutynin anticholinergic burden; temazepam sedative/deliriogenic); define target behaviours with ABC charting and NPI-style domains; risk and capacity/proxy map. High psychiatric morbidity in LTC means do not dismiss symptoms, but do not label every crisis as primary psychosis.[1][2]

(ii) Non-drug care. First-line is person-centred care, meaningful activity, sensory aids, consistent approach to personal care, and staff training. Fossey cluster RCT: enhanced psychosocial care reduced antipsychotic use in severe dementia nursing homes without significantly worsening behaviour. WHELD/person-centred packages improve quality of life and agitation metrics and can reduce antipsychotic use. Husebo: protocolised pain treatment reduces behavioural disturbance in nursing-home dementia — treat pain before escalating psychotropics. Stop or minimise oxybutynin and temazepam if safer alternatives exist.[4][5][6]

(iii) Antipsychotics. Benefits are modest and symptom-targeted for severe distress or danger only. Harms: Schneider meta-analysis — increased death with atypical antipsychotics in dementia RCTs; observational mortality and serious-event data (Gill/Huybrechts/Rochon class of evidence). If continued briefly for clear risk: lowest dose (e.g. risperidone 0.25–0.5 mg range), ECG/falls monitoring, documented target, consent/proxy, review/stop date. DART-AD: continuing neuroleptics is not clearly advantageous for many; long-term follow-up raised mortality concerns with continued treatment — plan deprescribing when stable.[3][7][8]

(iv) Restraint, capacity, disposition. Near-daily PRN without documented indication risks chemical restraint framing — document therapeutic purpose or stop. Capacity is decision-specific for psychotropic consent and transfer; engage proxy under local law. Disposition: optimise in place with old-age liaison/DBMAS-style support; hospital only if medical instability or risk exceeds facility capacity. Reassurance to staff that evidence-based non-drug care can reduce drug reliance is part of systems leadership.[2][4]

References

  1. [1]Seitz D, Purandare N, Conn D Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review Int Psychogeriatr, 2010.PMID 20522279
  2. [2]Kales HC, Gitlin LN, Lyketsos CG Assessment and management of behavioral and psychological symptoms of dementia BMJ, 2015.PMID 25731881
  3. [3]Schneider LS, Dagerman KS, Insel P Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials JAMA, 2005.PMID 16234500
  4. [4]Fossey J, Ballard C, Juszczak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial BMJ, 2006.PMID 16543297
  5. [5]Ballard C, Corbett A, Orrell M, et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial PLoS Med, 2018.PMID 29408901
  6. [6]Husebo BS, Ballard C, Sandvik R, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial BMJ, 2011.PMID 21765198
  7. [7]Ballard C, Lana MM, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial) PLoS Med, 2008.PMID 18384230
  8. [8]Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial Lancet Neurol, 2009.PMID 19138567